Skip to main content
main-content

09-15-2021 | ESC 2021 | Conference coverage | Video

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).

ESC Congress 2021 coverage

27 – 30 August: Browse all of the latest coverage


Image Credits